Correction to “HLA-B Associates With Distinct Disease Expression in Juvenile Spondyloarthritis: A Retrospective Cohort Study” - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Erratum for “HLA-B Correlates With Unique Disease Manifestations in Juvenile Spondyloarthritis: A Retrospective Cohort Analysis”

  • September 15, 2026

Share

Clinical Scorecard: Erratum for “HLA-B Correlates With Unique Disease Manifestations in Juvenile Spondyloarthritis: A Retrospective Cohort Analysis”

At a Glance

CategoryDetail
ConditionClinical topic addressed by the source article: Erratum for “HLA-B Correlates With Unique Disease Manifestations in Juvenile Spondyloarthritis
Key MechanismsHLA-B correlates with distinct disease manifestations in juvenile spondyloarthritis.
Target PopulationPatients or participants described in the source article.
Care SettingCare setting described in the source article.

Key Highlights

  • highlights

Guideline-Based Recommendations

Diagnosis

  • Include relevant diagnostic criteria for juvenile spondyloarthritis.

Management

  • Outline management strategies for juvenile spondyloarthritis.

Monitoring & Follow-up

  • Specify monitoring protocols for juvenile spondyloarthritis.

Risks

  • Identify potential risks associated with juvenile spondyloarthritis.

Patient & Prescribing Data

Include specific treatment options and considerations for juvenile patients with spondyloarthritis.

Clinical Best Practices

  • best_practices

Related Resources & Content

Original Source(s)

Correction to “HLA-B Associates With Distinct Disease Expression in Juvenile Spondyloarthritis: A Retrospective Cohort Study”

  • September 15, 2026

Related Content

JIA-Associated Uveitis in Adults

Ophthalmologists caring for adults with this condition may encounter persistent inflammation, treatment dependence, and the cumulative ocular effects of childhood disease.

FDA approves first therapy for warm autoimmune hemolytic anemia

The phase 2/3 ENERGY trial evaluated durable hemoglobin response with nipocalimab vs placebo in adults with warm autoimmune hemolytic anemia.

CD19 CAR T Therapy Tested in Refractory Rheumatoid Arthritis

Disease activity fell in all six participants in a phase I trial, with three achieving sustained drug-free remission during follow-up

  • September 8, 2026

  • 3 min